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Introduction
Many cells die each day in our body to establish tissue
homeostasis, to remove unwanted immune cells, in
development or during infections. Several tightly reg-
ulated pathways, called apoptosis, have evolved to
ensure the disposal of dying cells and their debris as
silent as possible without activating the immune sys-
tem [1]. In contrast, necrosis is primarily considered as
a non-silent pathway of cell death, which is supposed
to activate the immune system. Apoptosis can be
induced by different pathways, but finally all these
pathways lead to the same result: the coordinated
breakdown of cellular structures, of which the nucleus
is the most striking [2]. Therefore, nuclear changes have
been considered as the best applicable and most specif-
ic marker for apoptosis [3]. The nuclear changes include
the condensation and fragmentation of chromatin and
the clustering of many other nuclear components into
so-called heterogeneous ectopic RNP-derived struc-
tures (HERDS) [4]. Another feature of apoptosis, and
not necrosis, is the appearance of many blebs on the
cell surface, which contain cytoplasmic and nuclear
components [5]. Both the nuclear changes and the
appearance of surface blebs are early features of apop-
tosis, although their function is still unclear [2]. 
The autoimmune disease systemic lupus erythemato-
sus (SLE) is characterized by autoantibodies directed
mainly against nuclear structures [6,7]. The apoptotic
cell has been proposed as the source of nuclear autoanti-
gens targeted during lupus, since (i) nuclear autoanti-
gens were identified in apoptotic surface blebs [8]; (ii)
mice deficient in molecules involved in the removal of
apoptotic cells develop lupus-like autoimmunity [9,10];
(iii) apoptotic cells, especially in combination with den-
dritic cells (DCs) are able to activate autoreactive T cells
and induce an anti-nuclear immune response in mice
[11-13]; and (iv) autoantibodies from lupus patients and
mice preferably recognize modified proteins from apop-
totic cells [14-20]. 
Post-translational modifications of nuclear
autoantigens
Post-translational modifications of proteins, including
acetylation, phosphorylation, methylation and citrullina-
tion, play an important role in the regulation of protein
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function by changing for instance the interaction with
other proteins, the activity and/or the stability. There-
fore, it is logical that apoptosis involves the modifica-
tion of many proteins. Early during apoptosis nuclear
processes, such as transcription and mRNA splicing,
have to be deviated to transcribe genes encoding pro-
apoptotic proteins [21], and finally these processes are
fully terminated [2]. Post-translational modifications of
histones have an essential function in the regulation of
chromatin structure and gene transcription [22]. Indeed,
changes in the post-translational modifications of his-
tones have been identified in chromatin from apoptotic
cells. Thus, histone H2B is phosphorylated on Ser14
during apoptosis [23], which has been associated with
the condensation of chromatin [24]. In addition, changes
in the acetylation of histones H2A, H3 and H4 occur
during apoptosis [19,25-28]. In different cell lines, using
different apoptosis inducers, both apoptosis-associated
acetylation and deacetylation of histones have been
found. Interestingly, acetylated histone H4 is an impor-
tant target of autoantibodies from lupus mice and
patients [19]. In addition, injection of a H4 peptide
acetylated on Lys8, 12 and 16 aggravated disease symp-
toms in lupus mice, whereas the non-acetylated H4 pep-
tide showed no effect. A (pre-apoptotic) difference in the
acetylation and methylation of histones was found in
splenocytes form lupus mice compared to control mice
[29]. Ubiquitinated H2A was identified as a target for
lupus autoantibodies [30,31], however, so far only deu-
biquitination of histone H2A has been associated with
apoptosis [32]. Dephosphorylation and poly(ADP)-ribo-
sylation of histone H1 and phosphorylation of histone
H2A, H2A.X and H3 have also associated with apopto-
sis [33-36]. Finally, transglutamination of histone H2B
during apoptosis was found [37] and transglutamination
was proposed to prevent the leakage of proteins from
apoptotic cells [38]. Many other possible histone modi-
fications have not been studied in association with apop-
tosis, whereas most modified histones have not been
tested with autoantibodies from lupus mice and patients.
In addition, modifications of DNA, such oxidation or
methylation, can occur and might change the immuno-
genicity of DNA.
Modifications of RNA-associated proteins (RNPs)
have been associated with the regulation of mRNA tran-
scription and splicing [39]. Particularly, changes in the
phosphorylation have been associated with apoptosis.
SR proteins, which are important regulators of mRNA
splicing, are dephosphorylated during Fas-induced
apoptosis by protein phosphatase 1 [40]. Dephosphory-
lated SR proteins are specifically recognized by lupus
autoantibodies [41]. Phosphorylated RNA polymerase
II was one of the first identified modified targets of
lupus autoantibodies [42,43], however, changes in the
phosphorylation state of RNA polymerase II, which
determine its activity, have not been associated with
apoptosis so far [44]. In addition, changes in the methy-
lation level of Sm snRNPs have not been identified yet
during apoptosis, while symmetrically-dimethylated
arginine residues in the C-terminal tails of SmD1, D3
and BB' proteins are recognized by lupus autoantibodies
[45]. Probably, the most striking modified lupus
autoantigens associated with apoptosis is the spliceoso-
mal U1-70K snRNP. The U1-70K protein is one of the
U1 snRNP-specific proteins of the U1 snRNP particle
and plays an important role in the recognition of 5'
splice sites on mRNA. Several reports have described
that the apoptotic 40-kDa fragment of the U1-70K pro-
tein generated after caspase cleavage is much better rec-
ognized in denatured conditions by autoantibodies from
lupus mice and patients [16-18]. We have recently
described that during apoptosis a specific change in the
phosphorylation status of the U1-70K protein occurs
(Fig. 1) [20]. First, the phosphorylation of Ser140 in the
RNA recognition motif (RRM) increases directly after
the induction of apoptosis. Then, simultaneously with
the cleavage by caspase-3, a caspase-dependent dephos-
phorylation by protein phosphatase 1 of other residues
in the U1-70K protein takes place. Interestingly, a pep-
tide comprised of a sequence of the RNA binding
domain including the phosphorylated Ser140, is recog-
nized by autoreactive T cells [46].
In addition to post-translational modification,
cleavage by proteases, such as caspases and
granzymes, of many nuclear proteins occurs. Cleavage
can affect the recognition of the affected protein by
lupus autoantibodies [47]. 
Relocation of nuclear proteins
Morphological changes of the nucleus are considered to
be a specific feature of apoptosis. Condensation and
fragmentation of chromatin is a well-studied process
[48]; however, many parts of this mechanism remain
elusive. Caspases activate DNA cleaving enzymes such
as caspase activated DNase (CAD) [49]. In addition, pro-
teins such as the apoptosis-inducing factor (AIF) are
translocated from mitochondria to the nucleus [50]. Both
CAD and AIF are essential for the condensation of chro-
matin, although for different stages. In addition, the con-
densation of chromatin is associated with several modi-
fications of histones (as described above). Some changes
in the structure of chromatin might also result in the
exposure of neo-epitopes. During the condensation and
under the control of several DNases, chromatin starts to
fragment [49]. This fragmentation results finallyin the
release of small chromatin particles during late apoptosis
(also called secondary necrosis). These chromatin parti-
cles are able to stimulate the immune system if they are
bound to anti-chromatin autoantibodies [51]. Released
chromatin particles have been found to contain HMGB1,
a classical example of a damage-associated molecular
pattern (DAMP) or alarmin [52]. HMGB1-containing
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chromatin can stimulate the immune system and has
been identified in the circulation of lupus patients
[52,53].
While the chromatin condenses, other nuclear struc-
tures relocate into HERDS, which were described for the
first time in a paper by Biggiogera et al. [54, reviewed in
refs 4 and 55]. Early during apoptosis structures normal-
ly present in the interchromatin space, such as the inter-
chromatin granules (also called nuclear speckles),
perichromatin fibrils (sites of transcription) and
perichromatin granules cluster together in HERDS. This
clustering continues with the addition of domains of the
nucleolus, which probably makes this process irre-
versible [4]. HERDS are based on structures, such as the
interchromatin granules, which are resistant to proteases
and nucleases. Therefore, proteins inside HERDS could
be protected from degrading enzymes. HERDS contain
many RNA-associated autoantigens, such as the U1-70K
protein (Fig. 1 and ref [20]) and the Sm antigen [54],
which are not degraded since they are still detectable by
antibody probes. In addition, HERDS contain still
detectable RNA [56]. Recently, it was found that proteins
from the same nuclear structure show a different dynam-
ical relocation during early apoptosis and cluster in dif-
ferent parts in the apoptotic cell [57]. The morphology of
HERDS shown by electron microscopy shows the possi-
ble existence of specific domains inside HERDS (unpub-
lished personal observations). However, data on the con-
tents and mechanism leading to the formation of HERDS
are scarce. One can imagine that HERDS have a differ-
ent composition in different types of cells or under dif-
ferent conditions. In addition, the composition of
HERDS might be different between normal and lupus
situations.
Release into apoptotic microparticles and
encounter with the immune system
After the formation of HERDS and the condensation of
chromatin, these structures are partially or completely
relocated to blebs on the cell surface. This relocation is
dependent on the kinase ROCKI, which phosphorylates
myosin and regulates the formation of surface blebs [58].
Transglutaminase activity has been found on sites of the
cell membrane where apoptotic blebs are formed [59].
Transglutaminase is an enzyme that cross-links proteins
and might therefore be involved in the clustering of pro-
teins in structures like HERDS. Moreover, transglutami-
nase 2-deficient cells show a leakage of intracellular pro-
teins [38]. The formation of apoptotic blebs seems to be
a universal feature of apoptosis for many cells, although
a different blebbing between adherent cells and cells
growing in suspension has been described [60]. In addi-
tion, the formation of different kinds of blebs for one sin-
gle cell has been found [8]. Thus, it was shown that two
populations of surface blebs exist on keratinocytes,
where proteins from the endoplasmic reticulum, ribo-
somes and the RNP Ro52 relocate to the small blebs
while chromatin, Ro60, La and snRNPs relocate to the
larger blebs [8]. Autoantigens are exposed on the outside
of apoptotic blebs and can be bound by autoantibodies
[61,62]. Early during apoptosis, apoptotic blebs release
from the apoptotic cell as apoptotic microparticles leav-
ing the apoptotic cell body [63]. However, a detailed
characterization of apoptotic blebs/microparticles for
their contents and their stability is lacking so far. Impor-
tantly, most studies describe apoptotic cells that are
obtained by low-speed centrifugation of cell cultures.
When this method is applied apoptotic microparticles are
lost, and their effect is therefore not taken into account. 
The recognition of apoptotic cells by the immune
system has been described extensively [64]. Generally, it
is considered that apoptotic cells do not induce a pro-
inflammatory response or even induce tolerance [1] and
necrosis results in activation of the immune system.
However, the story is not black and white, since apop-
totic cells can propagate an immune response [65]. The
activation of the immune system depends partly on the
release of a recently identified class of molecules, the
alarmins [1,66]. These molecules which have their 'nor-
mal' function inside the cell, can also act as a cytokine
when released from the cell. In general, apoptotic cells
have several mechanisms to keep alarmins inside the cell
and prevent the activation of the immune system. These
mechanisms are still mostly unexplored, but studies on
the classic alarmin HMGB1 have revealed some impor-
tant information. HMGB1 is a protein involved in bend-
ing of dsDNA, but can be released from necrotic cells
and activate immune cells by binding to receptor of
advanced glycosylation products (RAGE) or Toll-like
receptor (TLR)-4 [65]. In apoptotic cells HMGB1 is kept
inside by binding to hypoacetylated chromatin [67].
However, apoptotic cells do release (some) HMGB1
[68,69], which is rendered inactive by reactive oxygen
species originating from mitochrondria [69]. Very late
apoptotic cells release chromatin particles, which con-
tain HMGB1 that can activate immune cells [70]. Inter-
estingly, chromatin isolated from the circulation of SLE
patients is bound to HMGB1. In addition, HERDS might
contain danger signals able to activate the immune sys-
tem. Recently, a new potential alarmin present in a RNA-
associated complex, i.e. SAP130 which is associated
with the U2 snRNP particle, was identified [71]. This
molecule could bind and activate marophages via the so-
called Mincle receptor, a new member of the C-type
lectin family. In addition, the RNA component of the U1
snRNP particle is able to activate TLR-7 [72,73]. In con-
clusion, chromatin and HERDS bound to danger mole-
cules might increase the potency of apoptotic micropar-
ticles to induce an autoimmune response. Indeed, the
activation of DCs by apoptotic bodies has been docu-
mented [74]. However, the mechanism leading to activa-
tion is not clear.
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Summary
Apoptotic cells should not induce an immune response
under normal circumstances; however, this seems
exactly what happens during the autoimmune disease
SLE. Why apoptotic cells or proteins derived from
apoptotic cells are able to induce an immune response
during SLE remains largely unexplained. As summa-
rized in this review, an increasing amount of evidence
points to the apoptotic processing of proteins, particu-
lar of nuclear origin, as an important event (Fig. 2).
Post-translational modifications of nuclear proteins
might lead to the exposure of neo-epitopes. Subse-
quently, modified nuclear proteins are reorganized
together with danger molecules (such as alarmins) into
condensed clusters, which may protect them from
nucleases and proteases. Apoptotic clusters are relocat-
ed to apoptotic blebs, which can be released as
microparticles when apoptotic cells are not removed in
time. Antigen-presenting cells are able to process these
structures in a pro-inflammatory context and activate
the immune system to produce autoantibodies against
apoptotically-processed nuclear proteins. Future
research has to fill in many of the gaps in this proposed
mechanism and may lead to the development of new
therapeutical approaches by preventing the activation
of the immune system by modified apoptotic structures.
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